C Kent Osborne Selected Research

Estrogens (Estrogen)

02/2008	Tamoxifen resistance in breast tumors is driven by growth factor receptor signaling with repression of classic estrogen receptor genomic function.
12/2006	Disruption of estrogen receptor DNA-binding domain and related intramolecular communication restores tamoxifen sensitivity in resistant breast cancer.
08/2006	Mechanisms of tumor regression and resistance to estrogen deprivation and fulvestrant in a model of estrogen receptor-positive, HER-2/neu-positive breast cancer.
11/2005	Advanced concepts in estrogen receptor biology and breast cancer endocrine resistance: implicated role of growth factor signaling and estrogen receptor coregulators.
09/2005	Estrogen receptor-positive, progesterone receptor-negative breast cancer: association with growth factor receptor expression and tamoxifen resistance.
04/2005	Molecular changes in tamoxifen-resistant breast cancer: relationship between estrogen receptor, HER-2, and p38 mitogen-activated protein kinase.
01/2005	Crosstalk between estrogen receptor and growth factor receptor pathways as a cause for endocrine therapy resistance in breast cancer.
09/2004	HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: a southwest oncology group study.
06/2004	Mechanisms of tamoxifen resistance: increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.
12/2003	Growth factor receptor cross-talk with estrogen receptor as a mechanism for tamoxifen resistance in breast cancer.
05/2003	Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.
03/2003	Role of the estrogen receptor coactivator AIB1 (SRC-3) and HER-2/neu in tamoxifen resistance in breast cancer.
01/2003	Breast cancer endocrine resistance: how growth factor signaling and estrogen receptor coregulators modulate response.

Articles by Research Topic

Disease

38	Breast Neoplasms (Breast Cancer) 09/2008 - 10/2002
4	Neoplasms (Cancer) 08/2006 - 05/2003
3	Carcinoma (Carcinomatosis) 07/2005 - 01/2003

Drug/Important Bio-Agent (IBA)

14	Tamoxifen FDA LinkGeneric 02/2008 - 03/2003
13	Estrogens (Estrogen)FDA Link 02/2008 - 01/2003
5	Progesterone Receptors (Progesterone Receptor)IBA 02/2006 - 05/2003
4	docetaxel (Taxotere)FDA Link 03/2008 - 08/2003
4	fulvestrant (Faslodex)FDA Link 08/2006 - 07/2003
3	HormonesIBA 04/2007 - 01/2005
3	Cyclophosphamide (Cytoxan)FDA LinkGeneric 02/2007 - 01/2003
2	Fluorouracil (Carac)FDA LinkGeneric 11/2005 - 01/2003
2	Methotrexate (Mexate)FDA LinkGeneric 11/2005 - 01/2003
2	anastrozole (Arimidex)FDA Link 07/2005 - 07/2003
2	Estrogen Receptor betaIBA 11/2004 - 05/2003
1	Formaldehyde (Formol)IBA 03/2008
1	ParaffinIBA 03/2008
1	Epidermal Growth Factor Receptor (EGF Receptor)IBA 05/2007
1	DNA receptor (receptor, DNA)IBA 12/2006
1	pegvisomant FDA LinkGeneric 08/2006
1	Somatotropin Receptors (Growth Hormone Receptor)IBA 08/2006
1	Biological Markers (Surrogate Marker)IBA 12/2005
1	Doxorubicin (Adriamycin)FDA LinkGeneric 11/2005
1	iodonitrotetrazolium (INT)IBA 09/2005
1	Protein Kinases (Protein Kinase)IBA 04/2005
1	trastuzumab (Herceptin)FDA Link 04/2005
1	Estrogen Receptor alphaIBA 01/2005
1	Genetic Markers (Genetic Marker)IBA 12/2003
1	bexarotene (LGD1069)FDA Link 03/2003
1	Prednisone (Sone)FDA LinkGeneric 01/2003
1	Phenylalanine (L-Phenylalanine)FDA Link 01/2003
1	Vincristine (Oncovin)FDA LinkGeneric 01/2003
1	Transcription Factor AP-1 (Transcription Factor AP 1)IBA 10/2002
1	Transcription Factors (Transcription Factor)IBA 10/2002

Therapy/Procedure

3	Heterologous Transplantation (Xenotransplantation) 09/2008 - 08/2006
3	Drug Therapy (Chemotherapy) 05/2008 - 07/2003
2	Adjuvant Chemotherapy 07/2003 - 01/2003
1	Therapeutics 03/2005
1	Segmental Mastectomy (Lumpectomy) 01/2005
1	Stem Cell Transplantation 07/2003